Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients사르데냐 다발성 경화증 환자에서 BNT162b2 백신에 대한 체액 반응에 대한 다양한 질병 수정 요법의 효과Immunology Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료법, [키워드] Acetate addition affected age Alemtuzumab analyzed anti-SARS-CoV-2 vaccine Antibody titer Antibody titers BNT162b2 BNT162b2 vaccine Clinical data clinically COVID-19 COVID-19 vaccine demographic difference dimethyl fumarate Disease-modifying therapy drug Effect Factor fingolimod followed by fumarate Glatiramer healthy control humoral immune response Humoral immunity Humoral response immune response infected with SARS-CoV-2 interferon investigated linear Male sex mixed-effects model mRNA mRNA-based Multiple multiple sclerosis objective observé of BNT162b2 Older age Patient patients patients treated Prevent response Result Sardinian SARS-CoV-2 SARS-COV-2 infection sclerosis second dose sera serology Sex significantly significantly higher significantly lower smoking smoking status statistically significant difference Teriflunomide tested therapy Treatment treatment group treatment groups uninfected untreated patients vaccination Vaccine vaccine efficacy were assessed [DOI] 10.3389/fimmu.2021.781843 PMC 바로가기 [Article Type] Immunology
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusArticle Published on 2021-12-092022-10-04 Journal: Nature Medicine [Category] 비임상, 임상, 치료제, [키워드] Administered Adverse antibody approved arthralgia Arthritis cause characterized Chikungunya virus clinical trial Concentration conducted detectable disease dose dose-dependent Effect evaluate evaluated Ex vivo expression Fever functional healthy Human IgG IgG level immunocompromised individual Immunoglobulin in vivo Infant Infection Infectious diseases interim analysis intravenous knowledge Messenger RNA Mild moderate monoclonal monoclonal antibody mRNA mRNA-based Neutralizing Neutralizing activity neutralizing antibody offer participant patients phase 1 trial Placebo placebo-controlled plasma concentration predicted Preventive medicine Primary outcome Randomized Rash serum severity single dose therapeutic therapeutic use therapy Tolerability Treatment Trial viral infection [DOI] 10.1038/s41591-021-01573-6 PMC 바로가기 [Article Type] Article
Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort복막 투석 환자에서 mRNA-1273 SARS-CoV-2 백신 접종 후 항체 반응 및 안전성 – 비엔나 코호트Immunology Published on 2021-12-022022-09-12 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] acute respiratory syndrome adverse event analyzed anti-SARS-CoV-2 Anti-SARS-CoV-2 S antibody Antibody Response Antibody titer Antibody titers Clinical course Cohort coronavirus COVID-19 dialysis dose early immune response examined Factor fatigue Fever first dose headache Hemodialysis high risk incidence Infection injection IQR joint Local Lower median Moderna mRNA-1273 mRNA-1273 vaccine mRNA-based myalgia occurred Pain Patient patients Peritoneal dialysis Regression model reported response Result retrospective Safety SARS-CoV-2 SARS-CoV-2 S score second dose Serious Adverse Events seroconversion rate seroconverted severity significantly spike systemic systemic AE systemic side effect vaccination Vaccine Vienna [DOI] 10.3389/fimmu.2021.780594 PMC 바로가기 [Article Type] Immunology
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs3 개의 승인 된 siRNA (Patisiran) 및 mRNA (COVID-19 백신) 약물에 사용 된 지질 나노 입자 기술의 차이Review Published on 2021-12-012022-08-31 Journal: Drug metabolism and pharmacokinetics [Category] MERS, 치료제, [키워드] approval approved approved drug biodistribution Candidates coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine moderna difference drug drugs effective delivery Elasomeran Genes Ionizable lipid Lipid Lipid nanoparticles LNP Medicine Moderna mRNA mRNA vaccine mRNA vaccines mRNA-based Onpattro outbreak Patisiran Pfizer-BioNTech provided remained Safe SARS-CoV-2 siRNA target cell target cells Tozinameran translation [DOI] 10.1016/j.dmpk.2021.100424 PMC 바로가기 [Article Type] Review
COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory AnalysisCOVID-19 백신 관련 혈전증: 체계적인 검토 및 탐색적 분석Immunology Published on 2021-11-292022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2 Adenovirus adenovirus-based Admission adverse effect adverse event adverse events affected age antibodies antibody appearance article assumed AstraZeneca Atypical binding caused complex Complication coronavirus disease Coronavirus disease 2019 correlation COVID-19 COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine Critical database Descriptive analysis DNA endothelial Endothelial cell endothelial cells events except for expressing Features female Genetic headache Health Organization heparin heparin-induced thrombocytopenia heterogeneity High-risk patients hypothese identify individual Inflammatory inoculation limit male material mechanism Moderna mRNA mRNA-based negative charge New normal range outcome pandemic pathophysiological mechanism pathophysiological mechanisms Patient performed petechiae PF4 PF4 antibodies Pfizer physiopathological mechanism Platelet Platelet count positive predisposition Prevalence prevalent Protein purpura recent remained Result review secondary to selected Symptom the patient thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenia vaccination Vaccine vaccine adverse effects vaccine complications vaccine-related thrombosis Vaccines variant venous venous sinus Viral viral DNA Viral vector viral vectors World Health Organization [DOI] 10.3389/fimmu.2021.729251 PMC 바로가기 [Article Type] Immunology
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and IssuesSystematic Review Published on 2021-11-242022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adverse events clinical trials COVID-19 COVID-19 vaccine COVID-19 vaccines Dexamethasone dose drug Effectiveness Efficacy Emergency use authorization European Medicines Agency events food Google Scholar Heterologous homologous inactivated Inactivated Vaccines issue limitations Medicine morbidity and mortality Mortality mRNA vaccine mRNA vaccines mRNA-based nanoparticle-based vaccines pandemic prime-booster strategy recombinant vaccines reducing reported review rising SARS-CoV-2 selected Seroconversion Side effect Side effects Surveillance systematic review Vaccine vaccine candidate Vaccines variant [DOI] 10.3390/vaccines9121387 PMC 바로가기 [Article Type] Systematic Review
Acute worsening of clinical presentation in CRPS after SARS-CoV-2 (COVID-19) vaccination: a case seriesCase Series Published on 2021-11-232022-10-28 Journal: Pain Management [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS, [키워드] Abstract case sery clinician complex coronavirus COVID-19 COVID-19 infection COVID-19 vaccination CRPS diagnosed Diagnosis General population Healthcare provider management morbidity Mortality mRNA mRNA-based Pain Patient patients RSD SARS-CoV-2 Symptom syndrome therapy type I vaccination worsening [DOI] 10.2217/pmt-2021-0089 PMC 바로가기 [Article Type] Case Series
Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cellsResearch article Published on 2021-11-222022-10-05 Journal: Molecular Therapy [Category] 비임상, [키워드] Alter approach cells clinical trials complexes conditions CRISPR/Cas9 Culture dampen defined described disadvantage DNA ENhance example expression gene editing Gene therapy hematopoietic stem cells Host identify Intracellular mechanism media mRNA mRNA-based NHP Nonhuman primate models notable Nuclease over platform progenitor cell Protein ribonucleoprotein RNase RNase inhibitor tested therapeutic Zinc-finger nuclease [DOI] 10.1016/j.omtm.2021.11.010 [Article Type] Research article
Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central EuropeArticle Published on 2021-11-162022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95% CI Active surveillance Administered Adverse adverse effects adverse event adverse events Adverse reactions Affect age Analysis AstraZeneca BTN162 mRNA vaccine Care carried concerning COVID-19 COVID-19 vaccination COVID-19 vaccines cross-sectional cross-sectional study demographic data Descriptive statistics doses Europe European country fatigue females groups headache healthcare healthcare personnel Healthcare workers increased risk injection Local Logistic regression Mild Moderna mRNA-based mRNA-based vaccine mRNA-based vaccines Occurrence optimization Pain parameters participant performed Pfizer-BioNTech Poland pooled analysis Prevalence proportion PROTECT question questionnaire reactogenicity recipient reported Result second dose secure selected significantly students systemic reaction systemic side effect vaccination Vaccine Vaccines vector vaccine viral vector-based vulnerable patients with COVID-19 worker [DOI] 10.3390/jcm10225338 PMC 바로가기 [Article Type] Article
Optimizing a Protocol to Assess Immune Responses after SARS-CoV-2 Vaccination in Kidney-Transplanted Patients: In Vivo DTH Cutaneous Test as the Initial Screening MethodCommunication Published on 2021-11-122022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-Spike IgG can be used Cellular immune response classical complement control patients correlation COVID19 Cutaneous delayed-type hypersensitivity dose DTH evaluated hypersensitivity IgG immunized Immunocompromised patient Immunosuppression in vitro in vivo interferon gamma kidney transplant mRNA-based natural infection Patient patients Pfizer–BioNTech positive recipient response SARS-CoV-2 Screening second dose shown Skin test T-cell T-cell functionality T-cell Response Test the spike protein the vaccine vaccinated individuals vaccination Vaccine was determined [DOI] 10.3390/vaccines9111315 PMC 바로가기 [Article Type] Communication